Harnessing the power of antibodies to fight bone metastasis

Sci Adv. 2021 Jun 23;7(26):eabf2051. doi: 10.1126/sciadv.abf2051. Print 2021 Jun.

Abstract

Antibody-based therapies have proved to be of great value in cancer treatment. Despite the clinical success of these biopharmaceuticals, reaching targets in the bone microenvironment has proved to be difficult due to the relatively low vascularization of bone tissue and the presence of physical barriers. Here, we have used an innovative bone-targeting (BonTarg) technology to generate a first-in-class bone-targeting antibody. Our strategy involves the use of pClick antibody conjugation technology to chemically couple the bone-targeting moiety bisphosphonate to therapeutic antibodies. Bisphosphonate modification of these antibodies results in the delivery of higher conjugate concentrations to the bone metastatic niche, relative to other tissues. In xenograft mice models, this strategy provides enhanced inhibition of bone metastases and multiorgan secondary metastases that arise from bone lesions. Specific delivery of therapeutic antibodies to the bone, therefore, represents a promising strategy for the treatment of bone metastatic cancers and other bone diseases.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies / therapeutic use
  • Bone Neoplasms* / drug therapy
  • Bone Neoplasms* / pathology
  • Bone Neoplasms* / secondary
  • Bone and Bones
  • Diphosphonates / therapeutic use
  • Heterografts
  • Humans
  • Mice
  • Neoplasm Metastasis / pathology
  • Tumor Microenvironment

Substances

  • Antibodies
  • Diphosphonates